INVA vs RPRX
INVA: A diversified biopharmaceutical company combining respiratory royalties from GSK blockbusters (BREO, ANORO) with a growing critical care and infectious disease platform (GIAPREZA, XACDURO, ZEVTERA, NUZOLVENCE). RPRX: Royalty Pharma is the leading financier of pharmaceutical innovation, providing capital in exchange for long-term royalty streams on top-tier commercial drug therapies.
Side-by-side fundamentals
| Metric | INVA | RPRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $21.43 | $58.72 | |
| Market cap as of 2026-07-23 | $1.6B | $33.8B | |
| P/E as of 2026-07-23 | 3.13 | 40.88 | INVA lower |
| PEG as of 2026-07-23 | n/a | 3.37 | |
| Net margin as of 2026-07-23 | +119.9% | +33.9% | INVA higher |
| Gross margin as of 2026-07-23 | +73.7% | n/a | |
| Operating margin as of 2026-07-23 | +38.1% | +65.1% | RPRX higher |
| ROE as of 2026-07-23 | +47.6% | +12.7% | INVA higher |
| ROA as of 2026-07-23 | +32.4% | +4.3% | INVA higher |
| Debt / equity as of 2026-07-23 | 0.19 | 1.30 | INVA lower |
| Revenue growth (YoY) as of 2026-07-23 | +13.8% | +7.8% | INVA higher |
| Revenue CAGR (3y) SEC XBRL | +7.5% | +2.1% | INVA higher |
| Dividend yield as of 2026-07-23 | n/a | +1.6% | |
| Dividend streak (yrs) SEC XBRL | 0 | 5 | RPRX higher |
| Beta as of 2026-07-23 | 0.34 | 0.43 | |
| 1-year return as of 2026-07-22 close | +10.7% | +62.7% | RPRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.